Latest / WTR Small-Cap Spotlight
Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market
Send us Fan Mail
We welcome back Veru's CEO Mitch Steiner to our latest WTR Small-Cap Spotligh podcast. In this podcast, Steiner gives us his thoughts on the latest trends in the rapidly evolving GLP-1 market for weight loss, discusses the data from enobosarm's Phase 2b data, and explains Veru's obesity drug development strategy in the wake of its recent positive interactions with the FDA.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.